$1.15 will be a great buy, page-142

their actual responsibility is to act in the best interests of shareholders. When that means reinvesting all their profits into growth, like every successful young biotech does, then that’s what they do. I’m sure you must understand that, and so are just repeating the profit issue for the benefit of your associated entity.
what I find reassuring is that this issue, and the other claim of there being competitive products, seem to be the only issues anyone tries to paint as a negative here. They are both obviously non-issues, so the continuous repetition of them just highlights the lack of any real ones.